Latest news with #AbdullaAlHashmi
Arabian Business
25-04-2025
- Business
- Arabian Business
Indian biotech firm Ayu Life Sciences to build $9mn Dubai facility for artificial skin
Ayu Life Sciences, an India-based medical devices and cell therapy company, announced plans to establish a new AED33 million ($9 million) advanced manufacturing facility at Jebel Ali Free Zone (Jafza). The new facility is billed as the first of its kind in the region. The 13,500 square metre facility will focus on the production of next-generation wound care solutions and surgical treatments, designed to meet the growing global demand for high-quality, sustainable healthcare products. India's Ayu expands globally Dr. Rajan Datt, Managing Director of Ayu Life Sciences, said the company is excited to announce the new facility in Jafza, marking a major milestone for it. 'We look forward to breaking ground on this new facility and extending the reach of our flagship products like Velgraft, Velvert, and VelNez to more patients in the Middle East and around the globe,' he said. Abdulla Al Hashmi, Chief Operating Officer Parks & Zones, DP World GCC, said Jafza's manufacturing infrastructure and strategic connectivity make it the ideal launchpad for innovators like Ayu Life Sciences. 'This facility reinforces Dubai's growing role as a global hub for the healthcare and advanced medical manufacturing sectors,' he said. The launch comes amid a surge in demand for artificial skin, with the market projected to grow from $3.1 billion in 2024 to $5.3 billion by 2032. The facility will be developed in two phases, with Phase 1 set to go live by late-2025, and full completion by 2027. It will produce Ayu Life Sciences' flagship products, including Velgraft, an artificial skin substitute designed for scar-free healing and tissue regeneration, Velvert, a natural antimicrobial wound care dressing formulated to accelerate healing and prevent infections, and VelNez, a nasal and ear dressing that enhances patient comfort and post-surgical recovery. These solutions are backed by a portfolio of 22 global patents and developed using eco-friendly materials and natural components to minimise environmental impact. The company currently exports from its Delhi facility to over 20 markets across North America, Europe, Asia, Australia, Africa, and the Middle East. In addition to advanced wound care, Ayu Life Sciences is progressing in the field of regenerative medicine. Clinical trials are underway for a novel therapy using cells similar to those in the pancreas to regulate blood sugar for patients with Type 1 diabetes, and for Velnerve, a solution for peripheral nerve injuries. With Jafza already home to over 800 manufacturing companies from 75 countries, Ayu Life Sciences joins a thriving ecosystem of global innovators.
Hi Dubai
25-04-2025
- Business
- Hi Dubai
Ayu Life Sciences Launches AED33 Million Manufacturing Facility in Jafza
Ayu Life Sciences is setting up a AED 33 million (US$9 million) advanced manufacturing facility in Dubai's Jebel Ali Free Zone (Jafza), marking a regional first for high-tech wound care and surgical treatments. Spanning 13,500 square metres, the new site will produce next-generation medical solutions, including artificial skin and antimicrobial dressings, aimed at meeting surging global demand for sustainable healthcare products. Phase 1 of the project is scheduled to be operational by late 2025, with full completion expected by 2027. The facility will manufacture Ayu Life Sciences' key products: Velgraft™, a skin substitute for scar-free healing; Velvert™, a wound care dressing that prevents infection; and VelNez™, a post-surgical nasal and ear dressing. These products are backed by 22 global patents and developed using eco-friendly, natural materials. The move comes as the artificial skin market is projected to grow from US$3.1 billion in 2024 to US$5.3 billion by 2032. Ayu Life Sciences currently exports to over 20 countries from its Delhi base, serving some of the world's most tightly regulated healthcare markets. The company is also advancing research in regenerative medicine, with clinical trials underway for a potential Type 1 diabetes therapy and a treatment for peripheral nerve injuries. Dr. Rajan Datt, Managing Director of Ayu Life Sciences, called the Jafza expansion a 'major milestone,' highlighting Dubai's strategic value in scaling access to innovative care across the Middle East and beyond. Abdulla Al Hashmi, COO of Parks & Zones at DP World GCC, noted that the move underscores Dubai's growing role in advanced medical manufacturing and reinforces Jafza's position as a launchpad for global healthcare innovation. News Source: Dubai Media Office
Trade Arabia
24-04-2025
- Business
- Trade Arabia
Ayu Life Sciences to set up $9m facility in Jafza
Ayu Life Sciences, a medical devices and cell therapy company, has announced plans to establish a new AED33 million ($9 million) advanced manufacturing facility at Jebel Ali Free Zone (Jafza), the first of its kind in the region. The 13,500-sq-m facility will focus on the production of next-generation wound care solutions and surgical treatments, designed to meet the growing global demand for high-quality, sustainable healthcare products. The launch comes amid a surge in demand for artificial skin, with the market projected to grow from $3.1 billion in 2024 to $5.3 billion by 2032. The facility will be developed in two phases, with Phase 1 set to go live by late-2025, and full completion by 2027. It will produce Ayu Life Sciences' flagship products, including Velgraft, an artificial skin substitute designed for scar-free healing and tissue regeneration; Velvert, a natural antimicrobial wound care dressing formulated to accelerate healing and prevent infections; and VelNez, a nasal and ear dressing that enhances patient comfort and post-surgical recovery. These solutions are backed by a portfolio of 22 global patents and developed using eco-friendly materials and natural components to minimise environmental impact. The company currently exports from its Delhi facility to over 20 markets across North America, Europe, Asia, Australia, Africa, and the Middle East, many with highly regulated healthcare markets. In addition to advanced wound care, Ayu Life Sciences is progressing in the field of regenerative medicine. Clinical trials are underway for a novel therapy using cells similar to those in the pancreas to regulate blood sugar for patients with Type 1 diabetes. Another trial is for Velnerve, a solution for peripheral nerve injuries. Dr Rajan Datt, Managing Director of Ayu Life Sciences, said: 'We're excited to announce our new facility in Jafza, marking a major milestone for Ayu Life Sciences. Our commitment to proprietary research and development enables us to consistently deliver excellent wound care products so we can continually push the boundaries of patient care. We look forward to breaking ground on this new facility and extending the reach of our flagship products like Velgraft, Velvert, and VelNez to more patients in the Middle East and around the globe.' Abdulla Al Hashmi, Chief Operating Officer Parks & Zones, DP World GCC, added: 'Jafza's manufacturing infrastructure and strategic connectivity make it the ideal launchpad for innovators like Ayu Life Sciences. This facility reinforces Dubai's growing role as a global hub for the healthcare and advanced medical manufacturing sectors. As we continue to grow, we remain committed to supporting cutting-edge industries that drive economic growth and improve lives.' -
Zawya
24-04-2025
- Business
- Zawya
Ayu Life Sciences to invest AED 33mln in medical manufacturing facility at JAFZA
Dubai, UAE – Ayu Life Sciences, a medical devices and cell therapy company, has announced plans to establish a new AED 33 million (US$9 million) advanced manufacturing facility at Jebel Ali Free Zone (Jafza), the first of its kind in the region. The 13,500 square metre facility will focus on the production of next-generation wound care solutions and surgical treatments, designed to meet the growing global demand for high-quality, sustainable healthcare products. The launch comes amid a surge in demand for artificial skin, with the market projected to grow from US$3.1 billion in 2024 to US$5.3 billion by 2032. The facility will be developed in two phases, with Phase 1 set to go live by late-2025, and full completion by 2027. It will produce Ayu Life Sciences' flagship products, including Velgraft™, an artificial skin substitute designed for scar-free healing and tissue regeneration; Velvert™, a natural antimicrobial wound care dressing formulated to accelerate healing and prevent infections; and VelNez™, a nasal and ear dressing that enhances patient comfort and post-surgical recovery. These solutions are backed by a portfolio of 22 global patents and developed using eco-friendly materials and natural components to minimise environmental impact. The company currently exports from its Delhi facility to over 20 markets across North America, Europe, Asia, Australia, Africa, and the Middle East, many with highly regulated healthcare markets. In addition to advanced wound care, Ayu Life Sciences is progressing in the field of regenerative medicine. Clinical trials are underway for a novel therapy using cells similar to those in the pancreas to regulate blood sugar for patients with Type 1 diabetes. Another trial is for Velnerve™, a solution for peripheral nerve injuries. Dr. Rajan Datt, Managing Director of Ayu Life Sciences, said: 'We're excited to announce our new facility in Jafza, marking a major milestone for Ayu Life Sciences. Our commitment to proprietary research and development enables us to consistently deliver excellent wound care products so we can continually push the boundaries of patient care. We look forward to breaking ground on this new facility and extending the reach of our flagship products like Velgraft™, Velvert™, and VelNez™ to more patients in the Middle East and around the globe.' Abdulla Al Hashmi, Chief Operating Officer Parks & Zones, DP World GCC added, 'Jafza's manufacturing infrastructure and strategic connectivity make it the ideal launchpad for innovators like Ayu Life Sciences. This facility reinforces Dubai's growing role as a global hub for the healthcare and advanced medical manufacturing sectors. As we continue to grow, we remain committed to supporting cutting-edge industries that drive economic growth and improve lives.' With Jafza already home to over 800 manufacturing companies from 75 countries, Ayu Life Sciences joins a thriving ecosystem of global innovators. This strategically positions the company to scale across the Middle East and beyond, leveraging Dubai's leading trade and logistics infrastructure. For DP World media enquiries, please contact: Jack Rigby Director Corporate Communications About Ayu Life Sciences Ayu Life Sciences is a leading healthcare company dedicated to transforming patient care through innovative medical devices and regenerative therapies. With a strong focus on research and development, the company boasts a robust portfolio of patented technologies and sustainable manufacturing practices. Ayu Life Sciences specializes in delivering advanced wound care, surgical solutions, and regenerative therapies designed to address some of the most pressing medical challenges worldwide. Headquartered in the UAE, the company partners with global distributors and healthcare providers to ensure exceptional quality, affordability, and accessibility in improving patient outcomes. About Jebel Ali Free Zone (Jafza) Jafza is one of the world's leading free trade zones and is home to over 10,890 multinational companies. Jafza accounts for a significant FDI (Foreign Direct Investment) flow into Dubai, sustaining the employment of more than 135,000 people in the United Arab Emirates. Strategically located at the crossroads of a region providing market access to over 3.5 billion people, Jebel Ali Port and Free Zone create an integrated multi-modal hub offering sea, air and land connectivity, complemented by extensive logistics facilities. Jafza is the leading business hub between Asia, Europe and Africa, connecting some of the fastest-growing manufacturing and consumer markets globally. With over 30 years' experience, Jafza focuses on long-term customer relationships, building alliances with global investors and providing world-class infrastructure and support. In addition to quality-driven value-added services and incentives, Jafza is a business opportunity enabler, offering its customers easy and efficient access to substantial business opportunities in the region.
ME Construction
03-04-2025
- Business
- ME Construction
JAFZA expands Logistics Park with investment of US $25mn
Infrastructure JAFZA expands Logistics Park with investment of US $25mn By The second phase comprises infrastructure, including modern offices, customisable units, temperature-controlled warehouses, loading docks, and power capacity to support diverse industries Jebel Ali Free Zone (JAFZA) has invested approximately US $25mn in Phase 2 of its Logistics Park. Adding 360,000sqft of Grade-A facilities, the expansion aligns with the UAE's push to grow its logistics sector to $54.5bn annually in the next seven years and cements Dubai's role in international trade. The second phase delivers infrastructure, including modern offices, customisable units, temperature-controlled warehouses, loading docks, and power capacity to support diverse industries. The Park, designed with sustainability in mind, incorporates precast concrete and off-site construction techniques to minimise its environmental impact. Additionally, it features skylights that maximise natural daylight, reducing energy consumption. Abdulla Al Hashmi, Chief Operating Officer, Parks & Zones, DP World GCC said, 'The expansion of JAFZA Logistics Park reflects our commitment to helping businesses compete globally and simultaneously drive foreign investment into Dubai. Phase 1 was fully leased before completion, highlighting strong demand for quality logistics and warehousing, Phase 2 takes this a step further offering flexible, high-quality solutions to support growth in multiple sectors. This brings the total area of Jafza Logistics Park to over 922,000sqft as we continue to grow our infrastructure.' With the Middle East and Africa's logistics market set to hit $235.8bn by 2031, demand for advanced warehousing is increasing, including in Dubai, where sectors like manufacturing, logistics, construction, and e-commerce are driving unprecedented growth. The park provides services such as packaging, labeling, and quality control, by real-time inventory tracking. Enables re-exports, domestic fulfillments, and import-export operations. The newly expanded park bridges this gap by providing market access, enhancing connectivity with Jebel Ali Port, offering storage and handling solutions. These solutions encompass contract logistics, freight forwarding, and freight management, catering to a diverse range of industries, including tech and automotive parts, fashion, and packaged food. The logistics hub currently houses 10,890 companies from 150 countries. These companies collectively support over 160,000 jobs and contribute $168.82bn annually to the global economy. Phase 1 of JAFZA's expansion, completed in November 2023, spans across 562,507sqft. This phase boasts Grade-A dry and pharmaceutical storage units, temperature-controlled warehouses, and office spaces.
